Pharma M&A in Action: Leveraging Bloomberg for Target Screening & Valuation
In today’s competitive pharmaceutical landscape, identifying the right acquisition or licensing opportunity is more critical than ever. How can you efficiently screen potential targets, assess the competitive landscape, and ensure accurate valuations?
Join us for this exclusive webinar to explore how Bloomberg’s suite of tools empowers pharma companies with data-driven decision-making in M&A. We’ll walk through a real-world workflow, showcasing how to leverage Bloomberg for:
Join us for this exclusive webinar to explore how Bloomberg’s suite of tools empowers pharma companies with data-driven decision-making in M&A. We’ll walk through a real-world workflow, showcasing how to leverage Bloomberg for:
- Target Screening – Identify promising assets in new therapy areas
- Competitive Landscape Analysis – Understand market positioning and key players
- Valuation & Deal Benchmarking – Evaluate fair market value and deal trends
Speakers
Kumar Ramamurthy
Healthcare Industry Specialist
Bloomberg
Kumar is a Healthcare Industry Specialist supporting Bloomberg's Corporations initiative where he covers Pharma companies within their M&A/Strategy/Corp Dev teams. He joined Bloomberg a year ago. Prior to joining Bloomberg, he spent 8 years in Investment Banking covering Healthcare M&A. He has worked in the M&A Teams at Morgan Stanley and UBS in London having served as an advisor on M&A deals, IPO/Capital Raise/Private Funding rounds as well as Defense Mandates.